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DiagnosisWe investigated the ability of cortical and subcortical graymatter (GM) atrophy in combination with whitemat-
ter (WM) integrity to distinguish behavioral variant frontotemporal dementia (bvFTD) from Alzheimer3s disease
(AD) and from controls using voxel-based morphometry, subcortical structure segmentation, and tract-based
spatial statistics. To determine which combination of MR markers differentiated the three groups with the
highest accuracy, we conducted discriminant function analyses. Adjusted for age, sex and center, both types of
dementia had more GM atrophy, lower fractional anisotropy (FA) and higher mean (MD), axial (L1) and radial
diffusivity (L23) values than controls. BvFTD patients had more GM atrophy in orbitofrontal and inferior frontal
areas thanADpatients. In addition, caudate nucleus and nucleus accumbenswere smaller in bvFTD than inAD. FA
values were lower; MD, L1 and L23 values were higher, especially in frontal areas of the brain for bvFTD com-
pared to AD patients. The combination of cortical GM, hippocampal volume and WM integrity measurements,
classiﬁed 97–100% of controls, 81–100% of AD and 67–75% of bvFTD patients correctly. Our results suggest that
WM integrity measures add complementary information to measures of GM atrophy, thereby improving the
classiﬁcation between AD and bvFTD.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer3s disease (AD) and behavioral variant frontotemporal
dementia (bvFTD) are the leading causes of young onset dementia
(Ratnavalli et al., 2002; Harvey et al., 2003). BvFTD has a very heteroge-
neous presentation, but is mostly characterized by a marked, progres-
sive decline in personality and/or behavior. Symptoms such as loss of
manners or decorum, impulsive actions, apathy and changing of eating
behavior are common (Rascovsky et al., 2011). Furthermore, patientslzheimer Center, VU University
he Netherlands. Tel.: +31 20
. This is an open access article underoften showdeﬁcits in cognitive domains of executive functioning, atten-
tion and working memory (Rabinovici et al., 2010; Hornberger et al.,
2008, 2012). AD is mainly characterized by episodic memory impair-
ment in the initial phase but deﬁcits in visuospatial abilities, executive
functioning, language and attention are also common (Nestor et al.,
2004; Smits et al., 2011). Clinical diagnostic criteria for bvFTD and AD
have been proposed (Rascovsky et al., 2011; McKhann et al., 2011),
but the frequent overlap of clinical symptoms associated with AD and
bvFTD and heterogeneity within one syndrome pose serious problems
in the differential diagnosis (Greicius et al., 2002; Miller et al., 2003;
Walker et al., 2005; Harris et al., 2015).
Although the deﬁnite diagnosis of both types of dementia is only
possible at autopsy, magnetic resonance imaging (MRI), providing
measurements of gray matter (GM) atrophy and white matter (WM)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stage. Studies on GM atrophy have shown precuneus, lateral parietal
and occipital cortices to be more atrophic in AD than in bvFTD, whereas
atrophy of anterior cingulate, anterior insula, subcallosal gyrus, and cau-
date nucleus was more severe in bvFTD compared to AD (Rabinovici
et al., 2007; Du et al., 2007; Looi et al., 2008). However, many scans dif-
fer from the predicted patterns of atrophy and overlap between AD and
bvFTD is common: GM loss in dorsolateral prefrontal cortex, medial
temporal lobes, hippocampus and amygdala is found in both AD and
bvFTD and does not help to discriminate between the two disorders
(Rabinovici et al., 2007; Munoz-Ruiz et al., 2012; van de Pol et al.,
2006; Barnes et al., 2006). Moreover, especially in the beginning of the
disease, cortical atrophy may not be visible by eyeballing.
In addition to local GM damage, a decrease of fractional anisotropy
(FA) in WM, suggesting WM tract damage has been shown, especially
in bvFTD. Previous studies showed that compared to AD, WM integrity
was lost in bvFTD especially in the frontal and bilateral temporal regions
(Zhang et al., 2009; Chen et al., 2009). Taking into account WM abnor-
malities holds promise to improve the distinction between AD and
bvFTD but only a few studies have been conducted so far (Zhang et al.,
2009;Mahoney et al., 2014). Moreover, it is conceivable that the combi-
nation of information from GM andWMmay help in the discrimination
between AD and bvFTD. Most former studies focused on either GM
or WM damage however, while only a few investigated the extent
to which the loss of WM integrity and GM atrophy are related and
how they jointly contribute to the clinical classiﬁcation of patients
(McMillan et al., 2012;Mahoney et al., 2014; Zhang et al., 2011). Gener-
alizability of these ﬁndings is limited as in one study patients from the
whole FTLD spectrum were compare to AD patients (McMillan et al.,
2012) and in other studies the different imaging modalities were
only linked to each other but not used for diagnostic discrimination
(Mahoney et al., 2014; Zhang et al., 2011).
In thismulti-center studywe compared patterns of cortical and sub-
cortical GM atrophy and of WM integrity between patients with bvFTD,
AD and controls with the ultimate goal to facilitate clinical diagnosis. In
addition, we investigated the joint discriminative ability of GM atrophy
andWM integritymeasurement todistinguish both patient groups from
controls and from each other.
2. Materials and methods
2.1. Patients
In this two center study, we included 39 patients with probable AD
and 30 patients with bvFTD, who visited either the Alzheimer Center
of the VU University Medical Center (VUMC) (probable AD: n = 23;
probable bvFTD: n= 16; possible bvFTD: n= 4) or the Alzheimer Cen-
ter of the Erasmus University Medical Center Rotterdam (probable AD:
n = 16; probable bvFTD: n = 9; possible bvFTD: n = 1). All patients
underwent a standardized 1-day assessment including medical history,
medical history (dementia, psychiatry, cardiovascular) of ﬁrst-degree
relatives, informant-based history, physical and neurological examina-
tion, blood tests, neuropsychological assessment, and MRI of the brain.
Diagnoses weremade in a multidisciplinary consensusmeeting accord-
ing to the core clinical criteria of the National Institute on Aging and the
Alzheimer3s Association work group for probable AD (McKhann et al.,
1984; McKhann et al., 2011) and according to the clinical diagnostic
criteria of FTD for bvFTD (Rascovsky et al., 2011). To minimize center
effects, all diagnoses were re-evaluated in a panel including clini-
cians from both centers. In addition, we included 41 cognitively
normal controls (VUMC: n = 23; Rotterdam: n = 18), who were re-
cruited by advertisement in local newspapers. Before inclusion in the
present study, controlswere screened formemory complaints, family his-
tory of dementia, drugs- or alcohol abuse, major psychiatric disorder, and
neurological or cerebrovascular diseases. They underwent an assessment
includingmedical history, physical examination, neuropsychologicalassessment, and MRI of the brain comparable to the work-up of
patients.
Inclusion criteria for both cohorts were: (1) availability of a T1-
weighted 3-dimensional MRI (3DT1) scan and a set of diffusion
weighted imaging (DWI) images designed to allow calculation of
the diffusion tensor at 3 T, and (2) age between 50 and 80 years. Exclu-
sion criteria were: (1) large image artifacts (n = 12); (2) failure of im-
aging analyzing software to process MR scans (n = 6); and (3) gross
brain pathology other than atrophy, including severe white matter
hyperintensities and/or lacunar infarction in deep gray matter struc-
tures. Level of education was rated on a seven-point scale (Verhage,
1964). The study was conducted in accordance with regional research
regulations and conformed to the Declaration of Helsinki. The local
medical ethics committee of both centers approved the study. All pa-
tients gave written informed consent for their clinical and biological
data to be used for research purposes.
2.2. Neuropsychological assessment
To assess dementia severity we used the Mini-Mental State Exami-
nation (MMSE). Cognitive functioning was assessed using a standard-
ized neuropsychological test battery covering ﬁve major domains:
memory (immediate recall, recognition and delayed recall of Dutch
version of the Rey Auditory Verbal Learning Test and total score of
Visual Association Test A), language (Visual Association Test picture
naming and category ﬂuency (animals: 1 min)), visuospatial function-
ing (subtest of Visual Object and Space Perception (VOSP) Battery:
number location), attention (Trail Making Test part A (TMT A), Digit
Span forward, and Letter Digit Substitution Test (LDST)), and executive
functioning (Digit Span backwards, Trail Making Test part B (TMT B),
letter ﬂuency, and Stroop Color–Word test, card III). For a detailed de-
scription of neuropsychological tests see (Smits et al., 2011). For each
cognitive task, z-scores were calculated from the raw test scores by
the formula z = (x− μ) / σ, where μ is the mean and σ is the standard
deviation of the subjective complaints group. The value z= 0 therefore
reﬂects the average test performance of the subjective complaints group
in a given domain. Scores of TMTA, TMT B, and Stroopwere inverted by
computing−1 × z-score, because higher scores imply a worse perfor-
mance. Next, composite z-scores were calculated for each cognitive do-
main by averaging z-scores. Composite z-scores were calculated when
at least one neuropsychological task was available in each cognitive
domain.
2.3. MR image acquisition and review
Imaging at the VUMC was carried out on a 3 T scanner (Signa HDxt,
GE Healthcare, Milwaukee,WI, USA), using an 8-channel head coil with
foam padding to restrict head motion. Patients and controls from the
Erasmus University Medical Center Rotterdam were all scanned at the
Leiden University Medical Center (LUMC). Imaging at LUMC was per-
formed on a 3 T scanner (Achieva, Philips Medical Systems, Best, The
Netherlands) using an 8-channel SENSE head coil.
The scan protocol included a whole-brain near-isotropic 3DT1-
weighted sequence for cortical and subcortical segmentation. At
VUMC this was a fast spoiled gradient echo sequence (FSPGR; repe-
tition time TR 7.8 ms, echo time TE 3 ms, inversion time TI 450 ms,
ﬂip angle 12°, 180 sagittal slices, voxel size 0.98 × 0.98 × 1 mm, total
scan time 4.57 min). At LUMC this was a turbo ﬁeld echo sequence
(T1TFE; TR 9.8 ms, TE 4.6 ms, ﬂip angle 8°, 140 transversal slices, voxel
size 0.88 × 0.88 × 1.2 mm, total scan time 4.57 min). In addition DWI
was performed using EPI based sequences. At the VUMC, DWI consisted
of ﬁve volumes without directional weighting (i.e. b = 0 s/mm2) and
30 volumes with noncollinear diffusion gradients (i.e. 30 directions,
b = 1000 s/mm2) and TR 13,000 ms, TE 87.8 ms, 45 contiguous axial
slices of 2.4 mm, voxel size = 2×2 × 2.4 mm, parallel imaging with
factor 2, total scan time 7.8 min. At the LUMC DWI consisted of 1 vol
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noncollinear diffusion gradients (i.e. 60 directions, b = 1000 s/mm2)
and TR 8250 ms, TE 80 ms, 70 axial slices, voxel size = 2×2 × 2 mm,
parallel imaging with factor 2, total scan time 9 min.
In addition, the MRI protocol included a 3D Fluid Attenuated Inver-
sion Recovery (FLAIR) sequence, dual-echo T2-weighted sequence,
and susceptibility weighted imaging (SWI) which were reviewed for
brain pathology other than atrophy by an experienced radiologist.
2.4. Gray matter volume
DICOM images of the 3DT1-weighted sequence were corrected for
gradient nonlinearity distortions and converted to Nifti format, after
which the image origin was automatically placed approximately on
the anterior commissure using a linear registration procedure. The
structural 3DT1 images were then analyzed using the voxel-basedmor-
phometry toolbox (VBM8; version 435; University of Jena, Department
of Psychiatry) in Statistical Parametric Mapping (SPM8; Functional Im-
aging Laboratory, University College London, London, UK) implemented
in MATLAB 7.12 (MathWorks, Natick, MA). In the ﬁrst module of the
VBM8 Toolbox (“Estimate andWrite”) the 3DT1 images are normalized
to MNI space and segmented into GM, WM and cerebrospinal ﬂuid
(CSF). We used the default settings, except for the clean-up, where we
used the light clean-up option to remove any remaining non-brain tis-
sue, as advised in the VBM8 tutorial. Tissue classes were normalized in
alignmentwith the templatewith the ‘non-linear only’ optionwhich al-
lows comparing the absolute amount of tissue corrected for individual
brain size. The correction is applied directly to the data, which makes
a head-size correction to the statistical model redundant. Subsequently,
all segmentations were checked with the second and third module of
the VBM8Toolbox (“Display one slice for all images” and “Check sample
homogeneity using covariance”) and by a one-by-one visual check. In
the fourth module, images were smoothed using an 8 mm full width
at half maximum (FWHM) isotropic Gaussian kernel.
Voxelwise statistical comparisons between groups weremade to lo-
calize GM differences by means of a full factorial design with diagnosis
(AD, bvFTD, controls) as factor with independent levels with unequal
variance, using absolute threshold masking with a threshold of 0.1
and implicit masking. Age, sex and center were entered as covariates.
Post hoc, we compared AD with controls, bvFTD with controls, and AD
with bvFTD. The threshold for signiﬁcance in all VBM analyses was set
to p b 0.05 with family wise error correction (FWE) at the voxel level
and an extent threshold of 0 voxel.
2.5. Volumes of deep gray matter (DGM) structures
The algorithm FIRST (FMRIB3s integrated registration and segmenta-
tion tool) (Patenaude et al., 2011) was applied to estimate left and right
volumes of ﬁve DGM structures: thalamus, caudate nucleus, putamen,
globus pallidus, and nucleus accumbens, and two medial temporal
lobe (MTL) structures: hippocampus and amygdala. Left and right
volumes were summed to obtain total volume for each structure.
FIRST is integrated in FMRIB3s software library (FSL 4.15) (Jenkinson
et al., 2012) and performed both registration and segmentation of the
abovementioned anatomical structures. A two-stage linear registration
was performed to achieve a more robust and accurate pre-alignment of
the seven structures. During the ﬁrst-stage registration, the 3DT1 im-
ages were registered linearly to a common space based on theMontreal
Neurological Institute (MNI) 152 templatewith 1×1×1mmresolution
using 12 degrees of freedom. After registration, a second stage registra-
tion using a subcortical mask or weighting image, deﬁned inMNI space,
was performed to improve registration for the seven structures. Both
stages used 12 degrees of freedom. This 2-stage registrationwas follow-
ed by segmentation based on shape models and voxel intensities. Vol-
umes of the seven structures were extracted in native space, taking
into account the transformations matrices during registration. Theﬁnal step was a boundary correction based on local signal intensities.
All registrations and segmentations were visually checked for errors.
To correct the volumes of the seven structures for head size we used
a volumetric scaling factor (VSF) derived from the normalization trans-
form matrix from SIENAX (Structural Image Evaluation using Nor-
malization of Atrophy Cross-sectional) (Smith et al., 2002), also
part of FSL. In short, SIENAX extracted skull and brain from the
3DT1 input whole-head image. In our study, brain extraction was
performed using optimized parameters (Popescu et al., 2012). These
were then used to register the subject3s brain and skull image to stan-
dard space brain and skull (derived fromMNI152 template) to estimate
the scaling factor (VSF) between the subject3s image and standard
space. Normalization for head size differences was done by multiply-
ing the raw volumes of the seven structures by the VSF. Next to the
VSF, we also obtained brain tissue volumes of GM and WM (Zhang
et al., 2001). Total volumes of the seven structures and volumes of
GM and WM, and VSF were transferred to SPSS for further statistical
analyses.
2.6. White matter integrity
All preprocessing steps of theDWI imageswere performed using FSL
(Jenkinson et al., 2012; Smith et al., 2004), includingmotion- and eddy-
current correction on images and gradient-vectors, followed by diffu-
sion tensor ﬁtting. Fractional anisotropy (FA), mean diffusivity (MD),
axial diffusivity (L1; largest eigenvalue), and radial diffusivity (L23;
average of the two smallest eigenvalues L2 and L3) were derived for
each voxel. Each subject3s FA image was used to calculate nonlinear
registration parameters to the FMRIB58_FA brain, which were then
applied to all four parameter images. The registered FA images were
averaged into a mean FA image, which was skeletonized for tract-
based spatial statistics (TBSS) (Smith et al., 2006). The skeleton was
thresholded at 0.2 to include only WM and used for TBSS statistics in
all diffusion parameters. Each subject3s aligned FA data was then
projected onto this skeleton and the resulting data fed into voxelwise
cross-subject statistics. The projection parameters for each voxel were
then also applied to the MD, L1 and L23 data to create skeletonized
data in standard space for each subject. Differences in FA, MD, L1
and L23 between controls, AD and bvFTD patients were analyzed in
a voxelwise fashion using FSL3s randomize with 5000 permutations
and age, sex and center as covariates. A family wise error (FWE)
corrected Threshold-Free Cluster Enhancement (TFCE) signiﬁcance
level of p b 0.05 was used to correct for multiple comparisons.
2.7. Extraction of regions of interest (ROI)
As a next step, we extracted ROIs from the VBM and TBSS group
analyses, to be able to combine the most promising MR markers in
one statistical model.
Gray matter ROIs (VBM): We extracted all signiﬁcant voxels
from the resulting T-maps from the comparisons AD b controls,
bvFTD b controls, and bvFTD b AD from the VBM analyses. This result-
ed in three GMROIs: ‘GMROI AD b Controls’, ‘GMROI bvFTD b Controls’,
‘GMROI bvFTD b AD’. This was done bymerging the normalized modu-
lated GM segments of all subjects into a 4D ﬁle. The T-maps of all con-
trasts were thresholded at p b 0.05 (FWE corrected) and binarized.
We then calculated the GM volume of each of the three ROIs and trans-
ferred it to SPSS for further analyses.
White matter integrity ROIs (TBSS): We extracted all signiﬁcant
voxels (TFCE, FWE corrected p b 0.05) from the statistical contrast
image from the comparisons AD b controls, bvFTD b controls, and
bvFTD b AD. This resulted in three FA ROIs: ‘FA ROI AD b Controls’,
‘FA ROI bvFTD b Controls’, ‘FA ROI bvFTD b AD’. We then calculated
the mean FA in each of the three ROIs. The same was done for MD, L1
and L23, resulting in three ROIs per diffusivitymeasurement. We trans-
ferred mean FA, MD, L1 and L23 of all ROIs to SPSS for further analysis.
Table 1
Demographics.
Controls AD bvFTD
N 37 32 24
Age, years 60.4 ± 6.2 66.7 ± 7.7a 63.2 ± 7.5
Sex, females (n, %) 16 (43%) 12 (38%) 6 (25%)
Center, VUMC 22 (60%) 22 (69%) 18 (75%)
Level of education 5.6 ± 1.0 5.0 ± 1.4 4.8 ± 1.6
Duration of symptoms
(months)
– 40.2 ± 4.6 50.0 ± 8.9
MMSE 28.9 ± 1.4 23.2 ± 3.1a 25.1 ± 3.1a,b
CDR 0 ± 0 0.8 ± 0.3a 0.8 ± 0.3a
GDS 1.1 ± 1.3 3.0 ± 3.1a 3.8 ± 2.9a
History of dementia (n, %) 24 (65%) 19 (61%) 8 (33%)a,b
History of Psychiatry (n, %) 3 (14%) 2 (9%) 5 (28%)
History of cardiovascular
events (n, %)
8 (36%) 14 (61%) 9 (47%)
Memory 0.0 ± 0.7 −5.1 ± 3.2a −2.4 ± 1.9a,b
Language −0.1 ± 0.9 −1.2 ± 1.6a −1.7 ± 1.5a
Visuospatial functioning 0.0 ± 1.0 −1.0 ± 1.9 −0.3 ± 1.0
Attention −0.1 ± 0.8 −2.3 ± 1.9a −1.5 ± 1.8a,b
Executive functioning 0.0 ± 0.8 −3.3 ± 2.5a −2.2 ± 2.3a
NBV (cm3) 1493.7 ± 64.1 1395.2 ± 76.2a 1394.81 ± 87.6a
VSF 1.3 ± 0.1 1.3 ± 0.1 1.3 ± 0.1
Values presented as mean ± standard deviation or n%. Level of education is determined
according to the Verhage-system. Differences between groups for demographics were
assessed using ANOVA, Kruskall–Wallis tests and χ2 tests, where appropriate.
Abbreviations:MMSE:Mini-Mental State Examination; CDR: Dementia Rating Scale; GDS:
Geriatric Depression Scale; NBV: normalized brain volume; VSF: volumetric scaling factor.
Cognitive composite z-domains were calculated of the available z-scores of each test by
the MEAN function in SPSS.
a Different from controls (p b 0.05).
b Different from AD (p b 0.05).
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SPSS version 20.0 for Windows was used for statistical analysis.
Differences between groups for demographics and cognition were
assessed using univariate analysis of variance (ANOVA) (age, VSF,
NBV), Kruskal–Wallis tests (level of education, MMSE, GDS, CDR,
composite cognitive domain z-scores) and χ2 test (sex, center, history
of dementia, psychiatry, cardio-vascular events in ﬁrst-degree relative).
Multivariate analysis of variance (MANOVA) was used to compare
total head-size corrected volumes of MTL and DGM structures
(dependent variables) between the different diagnostic groups
(between-subjects factor) with Bonferroni adjusted post hoc tests.
Age, sex and center were used as covariates.
To determine which combination of MR markers based on VBM,
DGM structures and TBSS measurements differentiated the three pa-
tient groups with the highest accuracy, we conducted a discriminant
function analysis with leave-one-out cross validation. As predictors we
entered the following variables: ‘GM ROI AD b Controls’, ‘GM ROI
bvFTD b Controls’, ‘GM ROI bvFTD b AD’; total head-size corrected
volumes of hippocampus, thalamus, caudate nucleus, putamen and
nucleus accumbens (as these structures signiﬁcantly differed between
the groups); ‘FA ROI AD b Controls’, ‘FA ROI bvFTD b Controls’, ‘FA ROI
bvFTD b AD’; as well as sex, age, and center. Because of colinearity we
performed another discriminant function analyses with the other diffu-
sion parameters L1 and L23 instead of FA. In this discriminant function
we used the following variables as predictors: ‘GM ROI AD b Controls’,
‘GM ROI bvFTD b Controls’, ‘GM ROI bvFTD b AD’; total head-size
corrected volumes of hippocampus, thalamus, caudate nucleus,
putamen and nucleus accumbens; ‘L1 ROI AD N controls’, ‘L1 ROI
bvFTD N controls’, ‘L1 ROI bvFTD N AD’, ‘L23 ROI AD N controls’, ‘L23
ROI bvFTD N controls’, ‘L23 ROI bvFTD N AD’; as well as sex, age, and
center.
In general, a discriminant analysis creates k-1 linear combinations
(discriminant functions) of the entered predictor variables which pro-
vides the best discrimination between the groups (k). To identify the
most optimal combination of variables for best discrimination, stepwise
forward analysis was usedwith a decision scheme based on the F-value
ofWilk3s lambda (entry: 3.84; removal: 2.71). Statistical signiﬁcance for
all analyses was set at p b 0.05.
3. Results
3.1. Demographics
Demographic and cognitive data for all patients (AD: n=32; bvFTD:
n = 24) and controls (n = 37) fulﬁlling inclusion criteria are summa-
rized in Table 1. AD patients were older than controls (p b 0.001);
there were no differences in gender distribution or education. Com-
pared to controls and AD, bvFTD patients had less ﬁrst degree relative
with dementia. Compared to controls, AD and bvFTD performed worse
on all cognitive domains, except on visuospatial functioning. Compared
to bvFTD patients, AD patients performed worse onmemory and atten-
tion. Both dementia groups had smaller normalized brain volumes than
controls (p b 0.001). AD patients had lower MMSE scores than both
other groups (p b 0.05). CDR and GDS scores were lowest in controls
(p b 0.001) but did not differ between the two dementia groups.
3.2. Gray matter volume
The full factorial design showed main effects of diagnosis (Fig. 1).
Post hoc comparisons showed that compared to controls, AD patients
showed a reduction of GM in superior and middle temporal gyrus,
parahippocampal gyrus, hippocampus, posterior cingulate, mid cingu-
lum, cuneus, precuneus, occipital lobe, superior and inferior parietal
lobe and inferior frontal gyrus (p b 0.05, FWE corrected). BvFTD pa-
tients had less GM compared to controls in superior, middle, andinferior frontal gyrus, orbito-frontal gyrus, insular, temporal gyrus,
parahippocampal gyrus and hippocampus. Controls did not show
any regions with less GM than AD or bvFTD (p b 0.05, FWE corrected).
Compared to AD patients, bvFTD patients had less GMmatter in left in-
ferior and medial frontal gyrus, in right inferior frontal gyrus, and in
orbitofrontal gyrus (p b 0.05, FWE corrected). AD patients did not
show any regions of signiﬁcantly reduced GM compared to bvFTD
patients. For comparisons between patient groups we also explored
the results at a non-corrected p= 0.001 level (ﬁgure in supplementary
materials): Compared to AD patients, bvFTD patients showed less GM in
orbitofrontal, inferior frontal, medial frontal lobe, temporal pole, fusi-
form gyrus and anterior cingulate. Compared to bvFTD patients, AD pa-
tients showed less GM in precuneus, posterior cingulate, occipital lobe,
angular gyrus and inferior parietal lobe.
3.3. Volumes of deep gray matter structures
Normalized volumes of MTL and DGM structures are summarized in
Table 2. MANOVA adjusted for age, sex and center revealed group
differences in hippocampus, thalamus, caudate nucleus, putamen and
nucleus accumbens (Fig. 2). Post hoc tests showed that nucleus accum-
bens and caudate nucleus volume discriminated all groups, with bvFTD
havingmost severe atrophy. Hippocampus and thalamus discriminated
dementia patients from controls. bvFTD patients had smaller putaminal
volumes than controls.
3.4. White matter integrity
Fig. 3 shows themean skeletonwith signiﬁcant regions in FA,MD, L1
and L23 for different group comparisons. Compared with controls, AD
patients showedwidespread patterns of lower FA values, incorporating
44% of the WM skeleton voxels, in areas including the fornix, corpus
callosum, forceps minor, thalamus, posterior thalamic radiation, su-
perior and inferior longitudinal fasciculus. Furthermore, they had
higher MD values in 36% of the WM skeleton voxels including the
Fig. 1. VBM voxel-wise statistical analysis of GM reductions between groups. Figures are displayed with a threshold of p b 0.05, FWE corrected. Brighter colors indicate higher t values.
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values in 23% of the WM skeleton voxels including the corpus
callosum, the corticospinal tract and inferior longitudinal fasciculus,
and higher L23 values in 42% of the WM skeleton voxels including
the forceps major, inferior fronto-occipital fasciculus, inferior and
superior longitudinal fasciculus and the corpus callosum compared
with controls.Table 2
Total volumes (cm3) of MTL and DGM structures, corrected for head size.
Controls AD bvFTD Ctrl N
p Mean
Hippocampus 10.3 ± 1.0 8.4 ± 1.5a 8.3 ± 1.4a b0.001 1.707
Amygdala 3.6 ± 0.6 3.4 ± 1.5 3.3 ± 0.6 0.082
Thalamus 19.8 ± 1.7 18.1 ± 2.0a 18.1 ± 1.7a b0.001 1.227
Caudate nucleus 9.0 ± 0.8 8.7 ± 0.9 8.0 ± 1.1a,b b0.001 0.128
Putamen 12.3 ± 1.1 11.2 ± 1.4 11.1 ± 1.4a 0.001 0.231
Globus pallidus 4.8 ± 0.7 4.6 ± 0.8 4.3 ± 0.8 0.071
Nucleus accumbens 1.1 ± 0.2 0.9 ± 0.3a 0.8 ± 0.2a,b b0.001 0.143
Values are presented as mean cm3 ± standard deviation. Comparisons are Bonferroni correcte
a Different from controls.
b Different from AD.Compared to controls, bvFTD patients showed widespread pat-
terns of lower FA values in 58% of the investigated WM voxels
throughout the whole brain, in areas including the fornix, corpus
callosum, forcepsminor, thalamus, anterior thalamic radiation, superior
and inferior longitudinal fasciculus and inferior fronto-occipital fascicu-
lus. Furthermore, they had higher MD values in 55% of the investigated
WM voxels including the inferior fronto-occipital fasciculus, uncinateAD Ctrl N bvFTD AD N bvFTD
difference p Mean difference p Mean difference p
b0.001 1.847 b0.001 0.140 1.000
0.006 1.689 b0.001 0.461 0.793
1.000 0.978 b0.001 0.850 0.002
0.631 1.118 0.001 0.485 0.364
0.031 0.331 b0.001 0.187 0.005
d with age, sex and center as covariates.
Fig. 2. Boxplot of volumes (cm3) of MTL and DGM structures. **p ≤ 0.001, *p b 0.05.
423C. Möller et al. / NeuroImage: Clinical 9 (2015) 418–429fasciculus and the forceps minor. They had higher L1 values in 39% of
the WM skeleton voxels including the inferior fronto-occipital fascicu-
lus, inferior longitudinal fasciculus, corticospinal tract and corpus
callosum, and higher L23 values in 62% of the investigated WM voxels
in the inferior and superior longitudinal fasciculus, corticospinal tract,
corpus callosum, fornix, inferior fronto-occipital fasciculus and the an-
terior thalamic radiation compared to controls.
In direct comparison between the two dementia groups, bvFTD
patients had lower FA values in 17% of the investigated voxels, solely
located in the frontal parts of the brain, like the rostrum and the genu
of the corpus callosum, forceps minor, anterior part of the internal and
external capsule, anterior parts of the fronto-occipital fasciculus and su-
perior longitudinal fasciculus. Furthermore, bvFTD patients had higher
MDvalues in 21% andhigher radial diffusivity values in 23% of the inves-
tigatedWMvoxels including forcepsminor, uncinate fasciculus, inferior
fronto-occipital fasciculus and anterior thalamic radiation, higher axial
diffusivity values in 14% of the investigatedWMvoxels including inferi-
or fronto-occipital fasciculus, uncinate fasciculus and forceps minor
compared to AD patients. AD patients had no areas of reduced diffusiv-
ity or increased fractional anisotropy compared to bvFTD.
3.5. Extraction of regions of interest (ROI)
In Fig. 4 the GM, FA, MD, L1 and L23 ROIs are depicted. The ROIs rep-
resent all signiﬁcant voxels from a two-group-comparison. In Table 3
compositions of the different ROIs are summarized.
3.6. Predictive value of GM volume, volumes of DGM structures, and white
matter integrity
Subsequently, we used discriminant analysis to identify the combi-
nation of MR-markers providing optimal classiﬁcation. Using stepwiseforward method, the ﬁrst discriminant analysis selected the following
predictors: (1) GMROI ADb Controls; (2) hippocampal volume; (3) vol-
umeof putamen; (4) FA ROI AD b Controls; (5) FAROI bvFTD b Controls;
(6) center; (7) age; and (8) sex. The two resulting discriminant func-
tions had a Wilk3s lambda of 0.082 (p ≤ 0.001) and 0.388 (p ≤ 0.001).
Fig. 5a shows the projection plot of the two canonical discriminant
functions for discrimination of the three groups. Discriminant function
1 discriminated AD from bvFTD and controls. Discriminant function
2 discriminated bvFTD from AD and controls. The loadings of the
individual predictors for each function are shown in Table 4a. GM ROI
AD b Controls had the highest loading on discriminant function 1.
Discriminant function 2 was primarily composed of the variables FA
ROI bvFTD b Controls, hippocampal volume, FA ROI AD b Controls, and
GM ROI AD b Controls. Cross-validation successfully classiﬁed 91.4% of
all cases correctly, with correct classiﬁcation of 100% of controls, 100%
of AD patients, and 66.7% of bvFTD patients.
The second discriminant analysis selected the following predic-
tors: (1) GM ROI AD b Controls; (2) GM bvFTD b AD; (3) L1 ROI
AD N Controls; (4) L1 ROI bvFTD N Controls; and (5) L1 ROI bvFTD N AD.
The two resulting discriminant functions had a Wilk3s lambda of 0.134
(p ≤ 0.001) and 0.437 (p ≤ 0.001). Fig. 5b shows the projection plot of
the two canonical discriminant functions for discrimination of the three
groups. Discriminant function 1 discriminated AD from bvFTD and con-
trols. Discriminant function 2 discriminated bvFTD from AD and con-
trols. The loadings of the individual predictors for each function are
shown in Table 4b. GM ROI AD b Controls and L1 ROI AD b Controls
had the highest loadings on discriminant function 1. Discriminant func-
tion 2 was primarily composed of GM ROI bvFTD b AD, L1 ROI
bvFTD b AD, L1 ROI bvFTD N Controls, GM ROI AD b Controls, and L1
ROI AD N Controls. Cross-validation successfully classiﬁed 86% of all
cases correctly, with correct classiﬁcation of 97.3% of controls, 81.3% of
AD patients, and 75% of bvFTD patients.
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Fig. 4. Composition of GM, FA, MD, L1 and L23 ROIs per contrast. Figures A–C show ROIs of reduced GM and lower FA. Figures D–F show ROIs of increasedMD, L1 and L23. (A) GM and FA
ROIs AD b controls: All signiﬁcant voxels (p b 0.05, FWE and FWE TFCE corrected) where AD patients had less GM (yellow) and lower FA values (red) compared to controls.(B) GM and FA
ROIs bvFTD b controls: All signiﬁcant voxels (p b 0.05, FWEand TFCE corrected)where bvFTDpatients had lessGM(yellow) and lower FA values (red) compared to controls.(C)GMand FA
ROIs bvFTD b AD: All signiﬁcant voxels (p b 0.05, FWE and FWE TFCE corrected)where bvFTDpatients had lessGM(yellow) and lower FA values (red) compared to ADpatients.(D)MD, L1
andL23ROIs ADN controls: All signiﬁcant areas (p b 0.05, FWETFCE corrected) from the TBSS group comparisonswhereADpatients had higherMD (pink), higher L1 (blue) and higher L23
(green) values compared to controls.(E)MD, L1 and L23ROIs bvFTD N controls: All signiﬁcant areas (pb 0.05, FWETFCE corrected) from the TBSSgroup comparisonswhere bvFTDpatients
had higherMD (pink), higher L1 (blue) and higher L23 (green) values compared to controls.(F)MD, L1 and L23 ROIs bvFTD N AD: All signiﬁcant areas (p b 0.05, FWE TFCE corrected) from
the TBSS group comparisons where bvFTD patients had higher MD (pink), higher L1 (blue) and higher L23 (green) values compared to AD patients.
Table 3
Composition of each ROI per group comparison for GM, FA, MD, L1 and L23 measurement.
Measurement Group
comparison
Brain regions incorporated in ROI
GM AD b Ctrl Temporal gyrus, posterior cingulate, cuneus, precuneus, inferior & superior parietal lobe, inferior frontal gyrus
FA Fornix, corpus callosum, forceps minor, thalamus, posterior thalamic radiation, superior & inferior longitudinal fasciculus
GM BvFTD b Ctrl Frontal gyrus, orbito-frontal gyrus, insula, temporal gyrus
FA Fornix, corpus callosum, forceps minor, thalamus, anterior thalamic radiation, superior & inferior longitudinal fasciculus, inferior fronto-occipital fasciculus
GM BvFTD b AD Left inferior & medial frontal gyrus, right inferior frontal gyrus, orbito-frontal gyrus
FA Rostrum & genu of corpus callosum, forceps minor, anterior part of internal & external capsule, anterior parts of fronto-occipital fasciculus, superior
longitudinal fasciculus
MD AD N Ctrl Fornix, corpus callosum, forceps minor, forceps major
L1 Corpus callosum, corticospinal tract, inferior longitudinal fasciculus
L23 Forceps major, inferior fronto-occipital fasciculus, inferior & superior longitudinal fasciculus, corpus callosum
MD BvFTD N Ctrl Inferior fronto-occipital fasciculus, uncinate fasciculus, forceps minor
L1 Inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, corticospinal tract, corpus callosum
L23 Inferior & superior longitudinal fasciculus, corticospinal tract, corpus callosum, fornix, inferior fronto-occipital fasciculus, anterior thalamic radiation
MD BvFTD N AD Forceps minor, uncinate fasciculus, inferior fronto-occipital fasciculus, anterior thalamic radiation
L1 Inferior fronto-occipital fasciculus, uncinate fasciculus, forceps minor
L23 Forceps minor, uncinate fasciculus, inferior fronto-occipital fasciculus, anterior thalamic radiation
Brain regions are listed where signiﬁcant voxels were detected from the group comparisons per measurement.
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Themain ﬁnding of this study is that there are GMand clearWMdif-
ferences between AD and bvFTDwhich both independently contributed
to the classiﬁcation of both types of dementia. Despite a comparable
disease stage, bvFTD patients had more atrophy in orbitofrontal and
inferior frontal areas, caudate nucleus and nucleus accumbens than
AD patients. Furthermore, they had more severe loss of FA, higher MD,Fig. 3. TBSS voxelwise statistics displaying areas of white matter skeleton (green) with lower FA
dard brain. Signiﬁcance level of p b 0.05 with correction formultiple comparisonswas used. Ske
on the original p-maps.L1 and L23 values, especially in the frontal areas. Combination ofmodal-
ities led to 86–91.4% correct classiﬁcation of patients. GM contributed
most to distinguishing AD patients from controls and bvFTD patients,
while WM integrity measurements, especially L1, contributed to distin-
guish bvFTD from controls and AD.
A large number of studies investigated the differences between
controls and AD or bvFTD patients with regard to either GM or WM
pathology. Their results are in line with the current study showing GM(red-yellow) and higher MD, L1, L23 (blue–light-blue) values, overlaid on the MNI-stan-
letonized results are thickened to enhance ﬁgure clarity. These thickened results are based
Fig. 5. Projection plot of canonical discriminant functions for discrimination of healthy
controls, AD and bvFTD patients. (a) Discriminant function consisted of GM ROI
AD b controls; hippocampal volume; volume of putamen; FA ROI AD b controls; FA ROI
bvFTD b controls; center; age; and sex. (b) Discriminant function consisted of GM ROI
AD b controls; GM bvFTD b AD; L1 ROI AD N controls; L1 ROI bvFTD N controls; and L1
ROI bvFTD N AD. Blue squares indicate individual data of healthy controls, green dots indi-
cate data of individual ADpatients, red triangles indicate individual data of bvFTDpatients.
The black squares represent the group centroids.
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in AD (Whitwell et al., 2011; Möller et al., 2013; Frisoni et al., 2002)
and atrophy of orbitofrontal, anterior cingulate, insula, lateral temporal
cortices, and caudate nucleus in bvFTD (Rabinovici and Miller, 2010;
Hornberger et al., 2011; Couto et al., 2013; Looi et al., 2012). DTI studies
on AD reported a rather consistent pattern of FA reductions in widely
distributed WM tracts exceeding MTL regions (Scola et al., 2010;
Agosta et al., 2011; Salat et al., 2010). In patients with bvFTD signiﬁcant
FA reductions in the superior and inferior longitudinal fasciculus, as
well as additional FA decreases in the uncinate fasciculus and the
genu of the corpus callosum have been reported (Borroni et al., 2007;
Matsuo et al., 2008).
To determine whether GM atrophy or WM integrity have potential
diagnostic use, a direct comparison between AD and bvFTD is more im-
portant than the comparison with a control group. With respect to GM
atrophy, precuneus, lateral parietal and occipital cortices have been
shown to bemore atrophic in AD than in bvFTD,whereas atrophy of an-
terior cingulate, anterior insula, subcallosal gyrus, and caudate nucleus
are more atrophic in bvFTD compared to AD (Rabinovici et al., 2007;
Du et al., 2007; Looi et al., 2008). In our study, we did not ﬁnd any
areas which are more atrophic in AD compared to bvFTD. This could
be explained by the strict FWE-corrected VBM approach, as we found
less GM in posterior brain regions in AD patients when not applying
the multiple comparisons correction. These results are in line with an-
other study not applying multiple comparisons correction (Rabinovici
et al., 2007). Another explanation that we did not ﬁnd any GM reduc-
tions in AD could be that our patients are included in an early disease
stage, with relatively higher MMSE scores compared to another study
(Du et al., 2007). Nevertheless, patterns of GM atrophy often overlap,
as there are numerous regions of GM loss which are found in both AD
and bvFTD (Rabinovici et al., 2007; Munoz-Ruiz et al., 2012; van de
Pol et al., 2006; Barnes et al., 2006). The few existing DTI studies
demonstrated WM alterations in FTD compared to AD, including more
widespread FA reductions in the frontal, anterior temporal, anterior cor-
pus callosum, inferior fronto-occipital fasciculus and bilateral anterior
cingulum (Zhang et al., 2009, 2011; Hornberger et al., 2011; Avants
et al., 2010;McMillan et al., 2012). One of these studies also investigated
the MD, L1 and L23 differences between FTD and AD and found in-
creased L1 and L23 values in FTD compared to AD (Zhang et al., 2009).
Our study is in line with these previous studies, failing to observe re-
duced FA and increased MD, L1 and/or L23 in AD relative to bvFTD.
The same is seen in the DGM structures, where bvFTD patients have
more subcortical brain damage compared to AD patients but not the
other way around (Looi et al., 2008, 2009; Halabi et al., 2013). The
combination of different imaging analysis methods suggests that the
non-cortical parts of the brain play an important role in bvFTD. Net-
works in bvFTD, consisting of white matter and deep graymatter struc-
tures,may be different compared to the cortical networks in AD. Indeed,
studies of functional connectivity show more functional network con-
nectivity in FTD compared to controls and AD (Filippi et al., 2013;
Zhou et al., 2010). Studies using multimodel network analyses should
focus on this topic in future studies.
We attempted to combine GM and WM measures to increase the
discrimination of patient groups and showed that next to GM atrophy,
WM integrity measures helped in distinguishing AD from bvFTD. A
few earlier studies have combined WM and GM information with the
objective to better discriminate between AD and bvFTD. They found
that FTD patients exhibited more WM damage than AD patients in an
early stage of the disease suggesting that measuring of WM damage
add up in the discrimination between these two dementias (Zhang
et al., 2011; Mahoney et al., 2014). Another study only linked the two
imaging modalities and support the idea of a network disease in FTD
but did not examine diagnostic value of GM and WM (Avants et al.,
2010). Only two studies actually used a multimodal combination of
WM and GM. In one study they achieved a classiﬁcation with 87% sen-
sitivity and 83% speciﬁcity between AD and bvFTD (McMillan et al.,2012). In another study they developed a new metric which gives a
measure of the amount of WM connectivity disruption for a GM region
and showed classiﬁcation rates were 8–13% higher when adding WM
measurements to GM measurements (Kuceyeski et al., 2012).
The novelty of the study lies in the combination of threemeasures to
separate AD from bvFTD.We combined VBMbasedmeasures of cortical
atrophy, FIRST based measures of atrophy of DGM structures and DTI
based measures of WM integrity to yield an optimal classiﬁer.
Table 4
Structure matrix showing the discriminant loadings for each predictor. The structure ma-
trix correlation coefﬁcient represents the relative contribution of each predictor to group
separation. (a) Discriminant analysis with GM ROIs, DGM structures and FA ROIs.
(b) Discriminant analysis with GM ROIs, DGM structures and L1 and L23 ROIs.
(a) Function
1 2
GM ROI ADbControls 0.469 0.449
Hippocampus 0.222 0.475
Putamen 0.111 0.282
FA ROI ADbControls 0.232 0.451
FA ROI bvFTDbControls 0.131 0.476
Center -0.021 -0.103
Age 0.187 0.111
Sex 0.003 -0.121
(b) Function
1 2
GM ROI ADbControls 0.642 0.400
GM ROI bvFTDbAD 0.039 0.706
L1 ROI bvFTDNAD 0.026 0.478
L1 ROI bvFTDNControls 0.183 0.433
L1 ROI ADNControls 0.303 0.329
The values shown in this table are the structure matrix correlation coefﬁcients, which are
the correlations between the variable and the discriminant function. The discriminant
function had a Wilk's lambda of 0.082 (p ≤ 0.001). No speciﬁc p-values for the structure
matrix correlation coefﬁcients are given.
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the separation of AD from the other two groups andWM integritymea-
surements contributed to the discrimination of bvFTD from the other
groups. Especially axial diffusivity increased the discriminatory power
for bvFTD. This could be explained by the notion that, despite some in-
volvement of DGM and WM, AD is assumed to be a cortical dementia
with speciﬁc GM regions being affected whereas bvFTD predominantly
affect areas (frontal-insula-anterior cingulate) which are part of struc-
turally and functionally connected neural networks. These networks
are connected by speciﬁc WM tracts located within damaged GM
areas as the frontal lobes and are preferentially affected, contributing
to network failure in bvFTD. The ﬁnding of more severe damage of
DGM structures add up to the hypotheses of bvFTD being a network
disorder as DGM structures can be seen as relay stations in the fronto-
striatal brain networks. These ﬁndings are further supported by the
fact that bvFTD had the same disease stage (comparable MMSE, CDR,
duration of symptoms) as AD patients but have more WM and DGM
structure damage.
A possible limitation of this study is that we did not have post-
mortem data available, so the possibility of misdiagnosis cannot be ex-
cluded. Nevertheless, we used an extensive standardized work-up and
all AD patients fulﬁlled clinical criteria of probable AD, 19 patients ful-
ﬁlled the criteria for probable bvFTD and 5 patients for possible bvFTD.
All diagnoses were re-evaluated in a panel including clinicians from
both centers to minimize sample effects. Because this is a multicenter
study, the differences in data acquisition parameters between the two
centers might introduce some noise in the DTI analysis. However, we
adjusted for center in all models and moreover, a recent study showed
that when considering scanner effects in the statistical model, no rele-
vant differences between scanners were found (Teipel et al., 2012). To
be conﬁdent that the different scanners did not essentially inﬂuence
the results, we repeated the TBSS analyses for a subtest of all subjects
of VUMConly and results remained essentially unchanged. Another lim-
itation could be the signiﬁcant age difference between the AD patients
and controls. However, we corrected for age in all analyses and repeated
the VBM, FIRST and TBSS analyses in an age matched subgroup which
did not change the results essentially. Among the strengths of this
study is the sample size and its multi-center nature. Most of the studiescomparing AD with bvFTD use smaller sample sizes. We had enough
power to detect differences using FWE and FWE-TFCE correction to
adjust for multiple comparisons. Another strength is the unique combi-
nation of three imaging parameters in this study to achieve optimal
discrimination between AD and bvFTD.5. Conclusion
Accurate diagnosis of patients in life is increasingly important, both
on clinical and scientiﬁc grounds. It is a guide to prognosis and prereq-
uisite for optimal clinical care and management. AD and bvFTD are dif-
ﬁcult to discriminate due to overlapping clinical and imaging features.
Therefore, there is an urgent need to improve diagnostic accuracy in a
quantitativemanner. This study has shown that DTI measures add com-
plementary information tomeasures of cortical and subcortical atrophy,
thereby allowing amore precise diagnosis between AD and bvFTD. If ac-
quisition, preprocessing and analyses methods are easier to implement
in the daily clinical routine, DTI could be incorporated in the standard
dementia MRI protocol in the future.Acknowledgements/disclosures
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